Trial Profile
Phase IIa proof-of-concept trial of CC8464 in patients with Erythromelalgia
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs CC 8464 (Primary)
- Indications Erythromelalgia
- Focus Proof of concept; Therapeutic Use
- Sponsors Chromocell Corporation
- 16 Feb 2024 According to a Chromocell Corporation media release, the net proceeds from the public offering will be used to prepare and begin conducting this trial.
- 06 Oct 2015 New trial record